New insights into insulin action and resistance in the vasculature

Annals of the New York Academy of Sciences

Volumn 1311, Issue 1, 2014, Pages 138-150

  Manrique, Camila ^a,b   Lastra, Guido ^a,b   Sowers, James R ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Endothelium; Insulin resistance; Nitric oxide; Obesity

Indexed keywords

ADENOSINE KINASE; ANTIOXIDANT; AT1R PROTEIN; AT2R PROTEIN; GLUCOSE; INCRETIN; INSULIN; INSULIN SENSITIZING AGENT; MEMBRANE PROTEIN; METFORMIN; POLYPHENOL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; DIET; EXERCISE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPOTOXICITY; MICROVASCULATURE; MOLECULAR MECHANICS; MUSCLE PERFUSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSGENIC ORGANISM; VASCULARIZATION; VASODILATATION;

CARDIOVASCULAR DISEASE; ENDOTHELIUM; INSULIN RESISTANCE; NITRIC OXIDE; OBESITY;

CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; INSULIN; INSULIN RESISTANCE; OBESITY; OVERWEIGHT; UNITED STATES;

EID: 84898409081     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12395     Document Type: Article

References (117)

1. Jeon, J.Y., S.H. Ko, H.S. Kwon, et al. 2013. Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J 37: 349-357.
2. Gupta, D., C. Krueger & G. Lastra. 2012. Over-nutrition, obesity and insulin resistance in the development of β-cell dysfunction. Curr. Diabetes Rev. 8: 76-83.
3. DeFronzo, R.A. & E. Ferrannini. 1991. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194.
4. Morrish, N., S. Wang, L. Stevens, et al. 2001. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44(Suppl 2): S14-S21.
5. Muniyappa, R. & S. Yavuz. 2012. Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act. Mol. Cell Endocrinol. 378: 59-69.
6. Muniyappa, R., M. Montagnani, K.K. Koh & M.J. Quon. 2007. Cardiovascular actions of insulin. Endocr. Rev. 28: 463-491.
7. Montagnani, M., L.V. Ravichandran, H. Chen, et al. 2002. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol. Endocrinol. 16: 1931-1942.
8. Montagnani, M., I. Golovchenko, I. Kim, et al. 2002. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J. Biol. Chem. 277: 1794-1799.
9. Michel, J.B., O. Feron, D. Sacks & T. Michel. 1997. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J. Biol. Chem. 272: 15583-15586.
10. Lin, M.I., D. Fulton, R. Babbitt, et al. 2003. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J. Biol. Chem. 278: 44719-44726.
11. Pritchard, K.A., Jr., A.W. Ackerman, E.R. Gross, et al. 2001. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J. Biol. Chem., 276: 17621-17624.
12. Crabtree, M. & K. Channon. 2011. Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide 25: 81-88.
13. Khimji, A. & D. Rockey. 2010. Endothelin: biology and disease. Cell Signal 22: 1615-1625.
14. Ferri, C., V. Pittoni, A. Piccoli, et al. 1995. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J. Clin. Endocrinol. Metab. 80: 829-835.
15. Zeng, G. & M. Quon. 1996. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest 98: 894-898.
16. Bender, S.B., A.P. McGraw, I.Z. Jaffe & J.R. Sowers. 2013. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes 62: 313-319.
17. DeFronzo, R. 2010. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53: 1270-1287.
18. Thiebaud, D., E. Jacot, R.A. Defronzo, et al. 1982. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 31: 957-963.
19. Barrett, E.J., H. Wang, C.T. Upchurch & Z. Liu. 2011. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am. J. Physiol. Endocrinol. Metab. 301: E252-E263.
20. Saltin, B., G. Radegran, M. Koskolou & R. Roach. 1998. Skeletal muscle blood flow in humans and its regulation during exercise. Acta Physiol. Scand. 162: 421-436.
21. Klitzman, B., D. Damon, R. Gorczynski & B. Duling. 1982. Augmented tissue oxygen supply during striated muscle contraction in the hamster. Relative contributions of capillary recruitment, functional dilation, and reduced tissue PO2. Circ. Res. 51: 711-721.
22. Segal, S.S. & T.L. Jacobs. 2001. Role for endothelial cell conduction in ascending vasodilatation and exercise hyperaemia in hamster skeletal muscle. J. Physiol. 536: 937-946.
23. Vincent, M.A., E.J. Barrett, J.R. Lindner, et al. 2003. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am. J. Physiol. Endocrinol. Metab. 285: E123-E129.
24. Womack, L., D. Peters, E. Barrett, et al. 2009. Abnormal skeletal muscle capillary recruitment during exercise in patients with type 2 diabetes mellitus and microvascular complications. J. Am. Coll. Cardiol. 53: 2175-2183.
25. Clark, M.G. 2008. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. Am. J. Physiol. Endocrinol. Metab. 295: E732-E750.
26. Bradley, E.A., M.G. Clark & S. Rattigan. 2007. Acute effects of wortmannin on insulin's hemodynamic and metabolic actions in vivo. Am. J. Physiol. Endocrinol. Metab. 292: E779-E787.
27. Ketel, I.J.G., C.D.A. Stehouwer, E.H. Serne, et al. 2008. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J. Clin. Endocrinol. Metab. 93: 3365-3372.
28. Liu, Z., S. Ko, W. Chai & W. Cao. 2012. Regulation of muscle microcirculation in health and diabetes. Diabetes Metab. J. 36: 83-89.
29. Ruotsalainen, U., M. Raitakari, P. Nuutila, et al. 1997. Quantitative blood flow measurement of skeletal muscle using oxygen-15-water and PET. J. Nucl. Med. 38: 314-319.
30. Nuutila, P., M. Raitakari, H. Laine, et al. 1996. Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J. Clin. Invest. 97: 1741-1747.
31. Clerk, L.H., S. Rattigan & M.G. Clark. 2002. Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes 51: 1138-1145.
32. Baron, A.D. 1994. Hemodynamic actions of insulin. Am. J. Physiol. Endocrinol. Metab. 267: E187-E202.
33. Baron, A.D., M. Laakso, G. Brechtel & S.V. Edelman. 1991. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J. Clin. Endocrinol. Metab. 73: 637-643.
34. Baron, A.D., M. Laakso, G. Brechtel, et al. 1990. Reduced postprandial skeletal muscle blood flow contributes to glucose intolerance in human obesity. J. Clin. Endocrinol. Metab. 70: 1525-1533.
35. Baron, A., H. Steinberg, H. Chaker, et al. 1995. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J. Clin. Invest. 96: 786-792.
36. Laakso, M., S. Edelman, G. Brechtel & A. Baron. 1990. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J. Clin. Invest. 85: 1844-1852.
37. Steinberg, H., G. Brechtel, A. Johnson, et al. 1994. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94: 1172-1179.
38. 2O, [18F]fluoro-2-deoxy-D-glucose, and positron emission tomography. Diabetes 45: 1471-1477.
39. Coggins, M., J. Lindner, S. Rattigan, et al. 2001. Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by capillary recruitment. Diabetes 50: 2682-2690.
40. Vincent, M.A., D. Dawson, A.D.H. Clark, et al. 2002. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes 51: 42-48.
41. Mehta, P.K. & K.K. Griendling. 2007. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292: C82-C97.
42. Lassegue, B. & K.K. Griendling. 2010. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb. Vasc. Biol. 30: 653-661.
43. Kim, J.-A., H.-J. Jang, L.A. Martinez-Lemus & J.R. Sowers. 2012. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am. J. Physiol. Endocrinol. Metab. 302: E201-E208.
44. Funke-Kaiser, H., J. Reinemund, U.M. Steckelings & T. Unger. 2010. Adapter proteins and promoter regulation of the angiotensin AT2 receptor: implications for cardiac pathophysiology. J. Renin-Angiotensin-Aldosterone Syst. 11: 7-17.
45. Tsutsumi, Y., H. Matsubara, H. Masaki, et al. 1999. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J. Clin. Invest. 104: 925-35.
46. Zhu, L., O.A. Carretero, T.-D. Liao, et al. 2010. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 56: 384-390.
47. Motta, G., R. Rojkjaer, A.A.K. Hasan, et al. 1998. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 91: 516-528.
48. Retailleau, K., E.J. Belin de Chantemele, S. Chanoine, et al. 2010. Reactive oxygen species and cyclooxygenase 2-derived thromboxane A2 reduce angiotensin II type 2 receptor vasorelaxation in diabetic rat resistance arteries. Hypertension 55: 339-344.
49. Savoia, C., Touyz, M. Volpe & E.L. Schiffrin. 2007. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 49: 341-346.
50. Chai, W, W. Wang, J. Liu, et al. 2010. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension 55: 523-530.
51. Chai, W., W. Wang, Z. Dong, et al. 2011. Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo. Diabetes 60: 2939-2946.
52. Wei, Y., J.R. Sowers, R. Nistala, et al. 2006. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J. Biol. Chem. 281: 35137-35146.
53. Steinberg, H., H. Chaker, R. Leaming, et al. 1996. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97: 2601-2610.
54. Keske, M.A., L.H. Clerk, W.J. Price, et al. 2009. Obesity blunts microvascular recruitment in human forearm muscle after a mixed meal. Diabetes Care 32: 1672-1677.
55. Muniyappa, R. & J.R. Sowers. 2013. Role of insulin resistance in endothelial dysfunction. Rev. Endocr. Metab. Disord. 14: 5-12.
56. Frisbee, J.C. 2003. Remodeling of the skeletal muscle microcirculation increases resistance to perfusion in obese Zucker rats. Am. J. Physiol. Heart Circ. Physiol. 285: H104-H111.
57. Jiang, Z.Y., Y.W. Lin, A. Clemont, et al. 1999. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 104: 447-457.
58. Potenza, M.A., F.L. Marasciulo, D.M. Chieppa, et al. 2005. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am. J. Physiol. Heart Circ. Physiol. 289: 25.
59. Liu, J., L.A. Jahn, D.E. Fowler, et al. 2011. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J. Clin. Endocrinol. Metab. 96: 438-446.
60. Samuel, V., K. Petersen & G. Shulman. 2010. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375: 2267-2277.
61. Rask-Madsen, C. & G.L. King. 2005. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb. Vasc. Biol. 25: 487-496.
62. Naruse, K., C. Rask-Madsen, N. Takahara, et al. 2006. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 55: 691-698.
63. Li, Q., K. Park, C. Li, et al. 2013. Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-beta isoform in the endothelium. Circ. Res. 113: 418-427.
64. Tabit, C.E., S.M. Shenouda, M. Holbrook, et al. 2013. Protein kinase C-beta contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 127: 86-95.
65. Jang, H.J., H.S. Kim, D.H. Hwang, et al. 2013. Toll-like receptor 2 mediates high-fat diet-induced impairment of vasodilator actions of insulin. Am. J. Physiol. Endocrinol. Metab. 304: 26.
66. Vicent, D., J. Ilany, T. Kondo, et al. 2003. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111: 1373-1380.
67. Duncan, E.R., P.A. Crossey, S. Walker, et al. 2008. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 57: 3307-3314.
68. Sukumar, P., H. Viswambharan, H. Imrie, et al. 2013. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 62: 2130-2134.
69. Gage, M.C., N.Y. Yuldasheva, H. Viswambharan, et al. 2013. Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: a role for reactive oxygen species. Atherosclerosis 230: 131-139.
70. Slaaby, R., L. Schaffer, I. Lautrup-Larsen, et al. 2006. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J. Biol. Chem. 281: 25869-25874.
71. Federici, M., O. Porzio, D. Lauro, et al. 1998. Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. J. Clin. Endocrinol. Metab. 83: 2911-2915.
72. Federici, M., O. Porzio, L. Zucaro, et al. 1997. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Mol. Cell Endocrinol. 135: 41-47.
73. Abbas, A., H. Imrie, H. Viswambharan, et al. 2011. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes 60: 2169-2178.
74. Imrie, H., H. Viswambharan, P. Sukumar, et al. 2012. Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice. Diabetes 61: 2359-2368.
75. Kearney, M.T. 2013. Changing the way we think about endothelial cell insulin sensitivity, nitric oxide, and the pathophysiology of type 2 diabetes: the FoxO is loose. Diabetes 62: 1386-1388.
76. Tsuchiya, K., J. Tanaka, Y. Shuiqing, et al. 2012. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab. 15: 372-381.
77. Tsuchiya, K. & D. Accili. 2013. Liver sinusoidal endothelial cells link hyperinsulinemia to hepatic insulin resistance. Diabetes 62: 1478-1489.
78. Lastra, G., S. Dhuper, M.S. Johnson & J.R. Sowers. 2010. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat. Rev. Cardiol. 7: 577-584.
79. Lastra-Lastra, G., J.R. Sowers, K. Restrepo-Erazo, et al. 2009. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin. Endocrinol. 71: 1-6.
80. Rossi, G., M. Boscaro, V. Ronconi & J.W. Funder. 2005. Aldosterone as a cardiovascular risk factor. Trends Endocrinol. Metab. 16: 104-107.
81. Ivanes, F., S. Susen, F. Mouquet, et al. 2012. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur. Heart J. 33: 191-202.
82. Hitomi, H., H. Kiyomoto, A. Nishiyama, et al. 2007. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50: 750-755.
83. Taniyama, Y., H. Hitomi, A. Shah, et al. 2005. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb. Vasc. Biol. 25: 1142-1147.
84. Draznin, B. 2006. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85{alpha}: the two sides of a coin. Diabetes 55: 2392-2397.
85. Sherajee, S.J., Y. Fujita, K. Rafiq, et al. 2012. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb. Vasc. Biol. 32: 257-263.
86. Xing, W., Y. Li, H. Zhang, et al. 2013. Improvement of vascular insulin sensitivity by downregulation of GRK2 mediates exercise-induced alleviation of hypertension in spontaneously hypertensive rats. Am. J. Physiol.: Heart Circ. Physiol. 305: H1111-H1119.
87. Shahid, G. & T. Hussain. 2007. GRK2 negatively regulates glycogen synthesis in mouse liver FL83B cells. J. Biol. Chem. 282: 20612-20620.
88. Usui, I., T. Imamura, J.L. Babendure, et al. 2005. G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol. Endocrinol. 19: 2760-2768.
89. Taguchi, K., T. Matsumoto, K. Kamata & T. Kobayashi. 2012. G protein-coupled receptor kinase 2, with beta-arrestin 2, impairs insulin-induced Akt/endothelial nitric oxide synthase signaling in ob/ob mouse aorta. Diabetes 61: 1978-1985.
90. Mikus, C.R., B.T. Roseguini, G.M. Uptergrove, et al. 2012. Voluntary wheel running selectively augments insulin-stimulated vasodilation in arterioles from white skeletal muscle of insulin-resistant rats. Microcirculation 19: 729-738.
91. Pierce, G.L., S.D. Beske, B.R. Lawson, et al. 2008. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension 52: 72-79.
92. Hamdy, O., S. Ledbury, C. Mullooly, et al. 2003. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 26: 2119-2125.
93. Maeda, S., S. Jesmin, M. Iemitsu, et al. 2006. Weight loss reduces plasma endothelin-1 concentration in obese men. Exp. Biol. Med. 231: 1044-1047.
94. Katakam, P.V., M.R. Ujhelyi, M. Hoenig & A.W. Miller. 2000. Metformin improves vascular function in insulin-resistant rats. Hypertension 35(1 Pt 1): 108-112.
95. Davis, B.J., Z. Xie, B. Viollet & M.H. Zou. 2006. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55: 496-505.
96. Diamanti-Kandarakis, E., K. Alexandraki, A. Protogerou, et al. 2005. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur. J. Endocrinol 152: 749-756.
97. Hong, J., Y. Zhang, S. Lai, et al. 2013. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36: 1304-1311.
98. Rahman, S.T., N. Merchant, T. Haque, et al. 2012. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study. J. Cardiovasc. Pharmacol. Ther. 17: 139-145.
99. Chen, H., R.J. Karne, G. Hall, et al. 2006. High-dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 290: 26.
100. Heitzer, T., B. Finckh, S. Albers, et al. 2001. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic. Biol. Med. 31: 53-61.
101. Beckman, J.A., A.B. Goldfine, M.B. Gordon, et al. 2003. Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 285: 24.
102. Kim, J.A. 2008. Mechanisms underlying beneficial health effects of tea catechins to improve insulin resistance and endothelial dysfunction. Endocr. Metab. Immune Disord. Drug. Targets 8: 82-88.
103. Reiter, C.E., J.A. Kim & M.J. Quon. 2010. Green tea polyphenol epigallocatechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: roles for AMP-activated protein kinase, Akt, and FOXO1. Endocrinology 151: 103-114.
104. Jang, H.J., S.D. Ridgeway & J.A. Kim. 2013. Effects of the green tea polyphenol, epigallocatechin-3-gallate (EGCG), on high fat diet-induced insulin resistance and endothelial dysfunction. Am. J. Physiol. Endocrinol. Metab. 22: 22.
105. Kuriyama, S., T. Shimazu, K. Ohmori, et al. 2006. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 296: 1255-1265.
106. Polychronopoulos, E., A. Zeimbekis, C.M. Kastorini, et al. 2008. Effects of black and green tea consumption on blood glucose levels in non-obese elderly men and women from Mediterranean Islands (MEDIS epidemiological study). Eur. J. Nutr. 47: 10-16.
107. Rizza, S., R. Muniyappa, M. Iantorno, et al. 2011. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 96: 2010-2879.
108. Misaka, S., J. Yatabe, F. Muller, et al. 2014. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin. Pharmacol. Ther. doi:10.1038/clpt.2013.241.
109. Drucker, D.J. 2006. The biology of incretin hormones. Cell Metab. 3: 153-165.
110. Nikolaidis, L.A., D. Elahi, T. Hentosz, et al. 2004. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961.
111. Nikolaidis, L.A., D. Elahi, Y.T. Shen & R.P. Shannon. 2005. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289: 15.
112. Zhao, T., P. Parikh, S. Bhashyam, et al. 2006. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317: 1106-1113.
113. Chai, W., Z. Dong, N. Wang, et al. 2012. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61: 888-896.
114. Liu, L., J. Liu, W.T. Wong, et al. 2012. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60: 833-841.
115. Shah, Z., C. Pineda, T. Kampfrath, et al. 2011. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 55: 2-9.
116. Scirica, B.M., D.L. Bhatt, E. Braunwald, et al. 2013. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369: 1317-1326.
117. White, W.B., C.P. Cannon, S.R. Heller, et al. 2013. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369: 1327-1335.